| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci |
NCT04725448: Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma |
|
|
| Recruiting | 2 | 27 | RoW | Toripalimab, JS001, Toripalimab Injection, TuoYI, Teruipuli Dankang, Bevacizumab, Bevacizumab Injection, Avastin, Bei Fa Zhu Dankang Zhusheye, Nab-paclitaxel, ABRAXANE, paclitaxel protein-bound particles for injectable suspension, Carboplatin, Carboplatin injection | Sichuan Cancer Hospital and Research Institute | Pulmonary Sarcomatoid Carcinoma, Non-small Cell Lung Cancer, Lung Diseases, Thoracic Neoplasms | 03/22 | 11/23 | | |
NCT03946943: Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma |
|
|
| Not yet recruiting | 2 | 25 | RoW | Anlotinib, Toripalimab, Blood Draw, Phlebotomy, Tumor Specimen Collection, Core-Needle Biopsy | Di Wu | Soft Tissue Sarcomas, Undifferentiated Pleomorphic Sarcoma | 07/22 | 07/23 | | |
| Recruiting | 2 | 200 | RoW | Toripalimab Combined With CAV/IE chemotherapy, CAV/IE alternate chemotherapy | Sun Yat-sen University | Soft Tissue Sarcoma | 01/25 | 06/26 | | |
| Recruiting | 2 | 74 | RoW | chidamide and toripalimab | Sun Yat-sen University | Sarcoma | 12/23 | 12/24 | | |
NCT04172805: Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma |
|
|
| Recruiting | 2 | 70 | RoW | anlotinib and toripalimab, Anlotinib Hydrochloride | Sun Yat-sen University | Sarcoma,Soft Tissue | 03/24 | 05/24 | | |
TORAN, ChiCTR2100054901: A phase II trial of anlotinib and toripalimab as maintenance therapy in patients with advanced soft tissue sarcoma after anthracycline-based chemotherapy |
|
|
| Recruiting | 2 | 50 | China | Anlotinib + Toripalimab | West China Hospital, Sichuan University ; West China Hospital, Sichuan University, West China Hospital, Sichuan University; Shanghai Junshi Biosciences Co., Ltd.; Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Soft tissue sarcoma | | | | |
NCT04785196: APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 95 | RoW | APG-115, Toripalimab | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Liposarcoma, Advanced Solid Tumor | 04/26 | 01/27 | | |
NCT05699811: IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 40 | RoW | MSC-IFNα, Nab paclitaxel, Abraxane, Cyclophosphamide, Anti-PD-1 monoclonal antibody, Toripalimab Injection, Sintilimab Injection, Camrelizumab Injection, Tislelizumab Injection | Chinese PLA General Hospital, Wuxi Sinotide New Drug Discovery Institutes | Locally Advanced or Metastatic Solid Tumors | 12/25 | 12/26 | | |
NCT05955105: A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies |
|
|
| Recruiting | 1/2 | 200 | RoW | ILB-2109, Toripalimab | Innolake Biopharm | Head and Neck Cancer, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Melanoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Classic Hodgkin Lymphoma | 01/26 | 07/26 | | |
